Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

Cancer statistics, 2018

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations

Life Sciences, Genetics, Molecular Biology +16

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · New England Journal of Medicine · 2016 · 2.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Carol Aghajanian, Stephanie V. Blank, Barbara A. Goff et al. · Journal of Clinical Oncology · 2012 · 1.4K citations · Full text

Medicine, Gynecology, Oncology +16